MedTrace Logo

imPlementing ROutine Molecular Characterization in Patients With Metastatic Castration Resistant ProstaTe Cancer by NGS

NCT04746300 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2021-02-09

No results posted yet for this study

Summary

The PROMPT study aims to routinely implement genomic pre-sorting of metastatic castration-resistant prostate cancer (mCRPC) patients for personalized treatment (e.g. immuno-, PARP inhibitors, or platinum-therapy). The investigators hypothesize that, by doing this early in the disease course (before exhausting standard of care options), it will improve treatment planning, patient outcome, quality of life, and reduce costs.

Conditions

Interventions

PROCEDURE

Biopsy

A biopsy will be taken from metastatic tissue, which will be used for DNA sequencing

PROCEDURE

Blood sample

Blood samples will be taken for additional translational research

Sponsors & Collaborators

  • VGZ health insurance (NL)

    collaborator UNKNOWN

  • Paul Speth Foundation (NL)

    collaborator UNKNOWN

  • Radboud Oncology Fund (NL)

    collaborator UNKNOWN

  • Radboud University Medical Center

    lead OTHER

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-04
Primary Completion
2024-02-29
Completion
2025-02-28

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04746300 on ClinicalTrials.gov